Literature DB >> 22747643

CYP2C19 genetic polymorphism in Saudi Arabians.

Fahad I Al-Jenoobi1, Khalid M Alkharfy, Amal M Alghamdi, Khawla M Bagulb, Abdullah M Al-Mohizea, Saleh Al-Muhsen, Rabih Halwani, Mohammad Khalid Parvez, Mohammed S Al-Dosari.   

Abstract

The main objective of this study was to evaluate CYP2C19 genetic polymorphism in a Saudi Arabian population by determining the frequencies of CYP2C19*2, *3, *4, *6, *7 and *17 alleles and their relevant genotypes. Genomic DNA was isolated from 192 healthy Saudi Arabians, representing different geographical regions, and genotyping of the selected CYP2C19 variants was carried out by direct sequencing after PCR amplification. The allelic frequency of heterozygous CYP2C19*2 was 8.2% with only one individual found to carry the homozygous genotype of this defective allele. None of the other investigated poor metabolizer alleles (i.e. CYP2C19*3, *4, *6 and *7) was detected in the study population. About 46% of the examined volunteers were found to carry CYP2C19*17 genotype (37.5% heterozygous and 8.1% homozygous of the defective allele) with an overall CYP2C19*17 allelic frequency of 26.9%. In addition, a novel CYP2C19 SNP (G356A) and another very rare SNP (C336T) have been identified in this study with a frequency of about 50% for each. Further studies are required to evaluate the metabolic and clinical relevance of CYP2C19*17, G356A and C336T in the Saudi Arabian population.
© 2012 The Authors Basic & Clinical Pharmacology & Toxicology © 2012 Nordic Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22747643     DOI: 10.1111/j.1742-7843.2012.00919.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  13 in total

Review 1.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

2.  Impact of CYP2C19 and CYP2C9 gene polymorphisms on sodium valproate plasma concentration in patients with epilepsy.

Authors:  Cangsang Song; Xingde Li; Panpan Mao; Wenbing Song; Lu Liu; Yang Zhang
Journal:  Eur J Hosp Pharm       Date:  2020-08-31

3.  The CYP2C19 genotypes and its effect on clopidogrel as an anti-platelet drug among the Arab population.

Authors:  Abdullah Alkattan; Yousef Almutairi; Eman Alsalameen; Ahmed Alkhalifah; Fatimah Alghanim
Journal:  Indian J Pharmacol       Date:  2021 Jan-Feb       Impact factor: 1.200

4.  Development of a High-Resolution Melting Analysis Method for CYP2C19*17 Genotyping in Healthy Volunteers.

Authors:  Zahra Ghasemi; Mehrdad Hashemi; Mahsa Ejabati; Seyyed Meisam Ebrahimi; Hamidreza Kheiri Manjili; Ali Sharafi; Ali Ramazani
Journal:  Avicenna J Med Biotechnol       Date:  2016 Oct-Dec

5.  Analysis of CYP2C19 Genetic Polymorphism in a Large Ethnic Hakka Population in Southern China.

Authors:  Zhixiong Zhong; Jingyuan Hou; Bing Li; Qifeng Zhang; Sudong Liu; Cunren Li; Zhidong Liu; Min Yang; Wei Zhong; Pingsen Zhao
Journal:  Med Sci Monit       Date:  2017-12-30

6.  CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome.

Authors:  Karin B Mirzaev; Elena M Zelenskaya; Olga L Barbarash; Vladimir I Ganyukov; Konstantin A Apartsin; Natalya O Saraeva; Konstantin Y Nikolaev; Kristina A Ryzhikova; Galina I Lifshits; Dmitry A Sychev
Journal:  Pharmgenomics Pers Med       Date:  2017-04-12

7.  Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy.

Authors:  Abdullah M Al-Rubaish; Fahad A Al-Muhanna; Abdullah M Alshehri; Mohammed A Al-Mansori; Rudaynah A Alali; Rania M Khalil; Khalid A Al Faraidy; Cyril Cyrus; Mohammed M Sulieman; Chittibabu Vatte; Daniel M F Claassens; Jurriën M Ten Berg; Folkert W Asselbergs; Amein K Al-Ali
Journal:  BMC Cardiovasc Disord       Date:  2020-06-03       Impact factor: 2.298

8.  The Effect of CYP2C19 and Nongenetic Factors on Clopidogrel Responsiveness in the MENA Region: A Systematic Review.

Authors:  Zainab Ali; Hazem Elewa
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

9.  Impact of CYP2C19 Polymorphisms on Serum Concentration of Voriconazole in Iranian Hematological Patients.

Authors:  Sholeh Ebrahimpour; Soha Namazi; Mehdi Mohammadi; Mohsen Nikbakht; Molouk Hadjibabaie; Hamidreza Taghvaye Masoumi; Ardeshir Ghavamzadeh
Journal:  J Res Pharm Pract       Date:  2017 Jul-Sep

10.  CYP2C19, PON1, and ABCB1 gene polymorphisms in Han and Uygur populations with coronary artery disease in Northwestern Xinjiang, China, From 2014 Through 2019.

Authors:  Tingting Wang; Ting Zhao; Sichen Bao; Li Jia; Jie Feng; Aiping Yu; Li Sun; Xihong Guo; Hongjian Li; Luhai Yu
Journal:  Medicine (Baltimore)       Date:  2020-07-17       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.